IP Library Granted Patent US 7,241,775
Granted Patent B2
US 7,241,775 · App. 10/807,781 · Granted Jul 10, 2007

Composition, process of making, and medical use of substituted 4-phenyltetrahydroisoquinolines

Assignee: Sanofi-Aventis Deutschland GmbH
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,241,775
App. No.
10/807,781
Granted
Jul 10, 2007
Kind
B2
Abstract

Substituted 4-phenyltetrahydroisoquinolines of formula I, process for their preparation, their use as a medicament and medicaments containing them. The compounds of formula I can be used, among other uses, in the event of renal disorders such as acute or chronic renal failure, in the event of disorders of biliary function, in the event of respiratory disorders such as snoring or sleep apneas or in the event of stroke.

Claims (288)

1. A compound of formula I, a pharmaceutically acceptable salt or a trifluoroacetate thereof

wherein:

R1, R2, R3 and R4 are each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO 2 , OH, an alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated, a cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated, O-alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with optionally some or all of the carbon atoms being fluorinated, O k —(CH 2 ) 1 -phenyl, heteroaryl having 0, 1, 2, 3 or 4 nitrogen atoms and 0 or 1 oxygen atom and 0 or 1 sulfur atom, O h —SO j —R10, NR14R15, CONR16R17, COOR18 and OCOR18, wherein

k is 0 or 1;

l is 0, 1, 2, 3 or 4;

h is 0 or 1;

j is 0, 1 or 2;

R10 is selected from the group consisting of alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated, OH, O-alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated, and NR11R12, wherein

R11 and R12 are each independently selected from the group consisting of hydrogen, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated and further having one or more CH 2 groups which may be replaced by O, NR13, CO, CS, where R13 is H or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated; or

R11 and R12 are both bonded to the nitrogen atom which is part of a 5- or 6-membered ring;

R14 and R15 are each independently selected from the group consisting of H, or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms fluorinated and further having one or more CH 2 groups which may be optionally replaced by 0, CO, CS or NR19, or

R14 and R15 are, together with the nitrogen atom which bonds them, part of a 5- or 6-membered ring;

R16 and R17 are each independently selected from the group consisting of H or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated and further having one or more CH 2 groups which may be replaced by O, CO, CS or NR19, or

R16 and R17 are, together with the nitrogen atom which bonds them, part of a 5- or 6-membered ring;

R18 is H or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated;

R19 is H or alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated;

R5 is selected from the group consisting of H, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated, COR20 and SO 2 R20; wherein

R20 is H or alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated;

R6 is selected from the group consisting of H, OH, F, Cl, Br, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated, O-alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated, and O-acyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated;

R7, R8 and R9 are each independently selected from the group consisting of H, F, Cl, Br, I, OH, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated, cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated, O-alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated, O v —SO w —R47, COR47, COOR60, NR51R52 and a hydrophilic -L-G group; wherein

v is 0 or 1;

w is 2 or 3;

R47 is selected from the group consisting of H, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated, and NR48R49; where

R48 and R49 are each independently H or alkyl which has 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated and further has one or more CH 2 groups which may be replaced by O, CO, CS or NR50, where

R50 is H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms with none, some or all of the carbon atoms being fluorinated;

Or, R48 and R49 are, together with the nitrogen atom which bonds them, part of a 5, 6, 7 or 8-membered ring;

R60 is H or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated;

R51 andR52 are each independently selected from the group consisting H, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated, and acyl which has 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated and further has one or more CH 2 groups which may be replaced by O or NR53, where

R53 is H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms with none, some or all of the carbon atoms being fluorinated;

or R5l and R52 are, together with the nitrogen atom which bonds them, part of a 5, 6, 7 or 8-membered ring;

L is selected from the group consisting of —NR30CO—, —CONR30-, —NR30CONR31- or —NR30COO—, and

R30 and R31 are each independently H, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated, or cycloalkyl having 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated;

G is a C a (OR32) x H 2a+1-x group which has one or more CH 2 groups that may be replaced by O or NR33, a C b (OR32) y H 2b-1-y group which has one or more CH 2 groups that may be replaced by O or NR33, a C c H 2c+1 group which has two or more CH 2 groups that may be replaced by O or NR33, or a —(CH 2 ) z —COOR34 group, a —(CH 2 ) z —SO 3 R34 group, a —(CH 2 ) z —N + R35R36R37 group where one or more hydrogen atoms of the —(CH 2 ) z units may be replaced by OR32, —CR38R39-COOR40 or —CR38R39NR41R42, where

a is 2, 3, 4, 5, 6 ,7 or 8;

x is 2, 3, 4, 5, 6 ,7 or 8;

R32 is H, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms with none, some or all of the carbon atoms being fluorinated, or acyl having 1, 2, 3, 4, 5 or 6 carbon atoms with none, some or all of the carbon atoms being fluorinated;

R33 is H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms with none, some or all of the carbon atoms being fluorinated;

b is 3, 4, 5, 6 or 7;

y is 2, 3, 4, 5, 6 or 7;

c is 3, 4, 5, 6, 7 or 8;

z is 0, 1, 2, 3 or 4;

R34, R35, R36 and R37 are each independently H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms of with none, some or all of the carbon atoms being fluorinated;

R38 is —(CH 2 ) n —Y; where

n is 0, 1, 2, 3 or 4;

Y is H, alkyl which has 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated and further has one or more CH 2 groups that may be replaced by O, S or NR43, or Y is —COOR44, —CONR45R46, —NHC(NH)NH 2 , phenyl or heteroaryl, said phenyl and heteroaryl radicals being capable of being substituted by up to three substituents selected from the group consisting of CH 3 , CF 3 , OH, OCH 3 and NH 2 ;

R43, R44, R45 and R46 are each independently H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms with none, some or all of the carbon atoms being fluorinated;

R39 is H or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated;

R40 is H or alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated;

R41 and R42 are each independently H, alkyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated, or acyl having 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms with none, some or all of the carbon atoms being fluorinated;

provided that at least one of the R7, R8 or R9 radicals in formula I is a -L-G group.

2. A compound of claim 1 , wherein:

R1, R2, R3 and R4, are each independently selected from the group consisting of H, F, Cl, Br, I, CN, NO 2 , OH, alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated, cycloalkyl having 3, 4, 5 or 6 carbon atoms with none, some or all of the carbon atoms being fluorinated, O-alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated, O-phenyl, SO 2 R10, NR14R15, CONR16R17, COOR18 and OCOR18; where

R10 is selected from the group consisting of alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated, OH and NR11R12; where

R11 and R12 are each independently selected from the group consisting of hydrogen, alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated, and acyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated,

or R11 and R12 are, together with the nitrogen atom which bonds them, part of a 5- or 6-membered ring which is of a type selected from the group consisting of 1-pyrrolyl, 1-piperidinyl, 1-piperazinyl, 1 -N-methylpiperazinyl and 4-morpholinyl;

R14 and R15 are each independently selected from the group consisting of H, alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated, and acyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated,

or R14 and R15 are, together with the nitrogen atom which bonds them, part of a 5- or 6-membered ring which is of a type selected from the group consisting of 1-pyrrolyl, 1-piperidinyl, 1-piperazinyl, 1-N-methylpiperazinyl and 4-morpholinyl;

R16 and R17 are each independently H or alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated,

or R16 and R17 are together with the nitrogen atom which bonds them, part of a 5- or 6-membered ring which is of a type selected from the group consisting of 1-pyrrolyl, 1-piperidinyl, 1-piperazinyl, 1-N-methylpiperazinyl and 4-morpholinyl;

R18 is H or alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated;

R5 is H, alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated, or cycloalkyl having 3, 4, 5 or 6 carbon atoms with none, some or all of the carbon atoms being fluorinated;

R6 is selected from the group consisiting of H, OH, F, Cl, Br, alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated, cycloalkyl having 3, 4, 5 or 6 carbon atoms with none, some or all of the carbon atoms being fluorinated, O-alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated, and O-acyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated;

R7, R8 and R9 are each independently selected from the group consisting of H, F, Cl, Br, I, OH, alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated, cycloalkyl having 3, 4, 5 or 6 carbon atoms with none, some or all of the carbon atoms being fluorinated, O-alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated, O v —SO w —R47, COR47, COOR60, NR51R52 and a -L-G group; where

v is 0 or 1;

w is 2 or 3;

R47 is H, alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated, or NR48R49; where

R48 and R49 are each independently H, alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated, or acyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated,

or R48 and R49 are, together with the nitrogen atom which bonds them, part of a 5- or 6-membered ring which is of a type selected from the group consisting of 1-pyrrolyl, 1-piperidinyl, 1-piperazinyl, 1-N-methylpiperazinyl and 4-morpholinyl;

R60 is H, alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated;

R51 and R52 are each independently H, alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated, or acyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated,

or R51 and R52 are, together with the nitrogen atom which bonds them, part of a 5- or 6-membered ring which is of a type selected from the group consisting of 1-pyrrolyl, 1-piperidinyl, 1-piperazinyl, 1-N-methylpiperazinyl and 4-morpholinyl;

L is —NR3 CO—, —CONR30-, —NR30CONR31-, —NR30COO— wherein R30 and R31 are each independently H, alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated, or cycloalkyl having 3, 4, 5 or 6 carbon atoms with none, some or all of the carbon atoms being fluorinated;

G is a C a (OR32) x H 2a+1-x group which has one or more CH 2 groups that may be replaced by O or NR33, a C b (OR32) y H 2b−1-y group which has one or more CH 2 groups that may be replaced by O or NR33, a C c H 2c+1 group which has two or more CH 2 groups being replaced by O or NR33, a —(CH 2 ) z —COOR34 group, a —(CH 2 ) z —SO 3 R34 group, a —(CH 2 ) z —N + R35R36R37 group which has one or more hydrogen atoms of the —(CH 2 ) z units that may be replaced by OR32 groups, a —CR38R39-COOR40 group, or a —CR38R39NR41R42 group; where

a is 2, 3, 4, 5, 6, 7 or 8;

x is 2, 3, 4, 5, 6, 7 or 8;

R32 is H, alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated, or acyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated;

R33 is H or alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated;

b is 3, 4, 5, 6 or 7;

y is 2, 3, 4, 5, 6 or 7;

c is 3, 4, 5, 6, 7 or 8;

z is 0, 1, 2, 3 or 4;

R34, R35, R36 and R37 are each independently H or alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated;

R38 is —(CH 2 ) n —Y; where

n is 0, 1, 2, 3 or 4;

Y is H or alkyl which has 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated and further has one or more CH 2 groups that may be replaced by O, S or NR43, or Y is COOR44, CONR45R46, NHC(NH)N 2 , phenyl or heteroaryl, whre the phenyl or heteroaryl radicals may be substituted by Lip to three substituents selected from the group consisting of CH 3 , CF 3 , OH, OCH 3 and NH 2 ;

R43, R44, R45 and R46 are each independently H or alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated;

R39 is H or alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated;

R40 is H or alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated;

R41 and R42 are each independently H, alkyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated, or acyl having 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated;

provided that at least one of the R7, R8 or R9 is an -L-G group.

3. A compound of claim 2 wherein,

R1, R2, R3 and R4, are each independently selected from the group consisting of H, F, Cl, Br, CN, NO 2 , OH, CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 , OCH 3, OCH 2 CH 3 , OCF 3 , OCH 2 CF 3 , SO 2 R10, NR14R15, CONR16R17, COOR18 and OCOR18, where

R10 is CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 , OH, or NR11R12, where

R11 and R12 are each independently H, CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 , COCH 3 , COCH 2 CH 3 , COCF 3 or COCH 2 CF 3 ,

or 11 and R12 are, together with the nitrogen atom which bonds them, part of a 5- or 6-membered ring which is of a type selected from the group consisting 1-pyrrolyl, 1-piperidinyl, 1-piperazinyl, 1-N-methylpiperazinyl and 4-morpholinyl;

R14 and R15 are each independently H, CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 , COCH 3 , COCH 2 CH 3 , COCF 3 or COCH 2 CF 3 ,

or R14 and R15 are, together with the nitrogen atom which bonds them, part of a 5- or 6-membered ring which is of a type selected from the group consisting of 1-pyrrolyl, 1-piperidinyl, 1-piperazinyl, 1-N-methylpiperazinyl and 4-morpholinyl;

R16 and R17 are each independently H, CH 3 , CH 2 CH 3 , CF 3 or CH 2 CF 3 ,

or R16 and R17 are, together with the nitrogen atom which bonds them, part of a 5- or 6-membered ring which is of a type selected from the group consisting of 1-pyrrolyl, 1-piperidinyl, 1-piperazinyl, 1-N-methylpiperazinyl and 4-morpholinyl;

R18 is H, CH 3 , CH 2 CH 3 , CF 3 or CH 2 CF 3 ;

R5 is H, CH 3 , CH 2 CH 3 , CF 3 or CH 2 CF 3 ;

R6 is H, OH, CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 , OCH 3 , OCH 2 CH 3 , OCF 3 , OCH 2 CF 3 ;

R7, R8 and R9 are each independently H, F, Cl, Br, I, OH, CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 , OCH 3 , OCH 2 CH 3 , OCF 3 , OCH 2 CF 3 , SO 2 R47, SO 3 R60, COR47, COOR60, NR51R52 or a -L-G group; where

R47 is H, CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 or NR48R49; where

R48 and R49 are each independently H, CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 , COCH 3 , COCH 2 CH 3 , COCF 3 or COCH 2 CF 3 ,

or R48 and R49 are, together with the nitrogen atom which bonds them, part of a 5- or 6-membered ring which is of a type selected from the group consisting of 1-pyrrolyl, 1-piperidinyl, 1-piperazinyl, 1-N-methylpiperazinyl and 4-morpholinyl;

R60 is H, CH 3 , CH 2 CH 3 , CF 3 , or CH 2 CF 3 ;

R51 and R52 are each independently H, CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 , COCH 3 , COCH 2 CH 3 , COCF 3 or COCH 2 CF 3 ,

or R51 and R52 are, together with the nitrogen atom which bonds them, part of a 5- or 6-membered ring which is of a type selected from the group consisting of 1-pyrrolyl, 1-piperidinyl, 1-piperazinyl, 1-N-methylpiperazinyl and 4-morpholinyl;

L is —NR30CO—, —CONR30-, —NR30CONR31-, or —NR30COO—, and where

R30 and R31 are each independently H, CH 3 , CH 2 CH 3 , CF 3 or CH 2 CF 3 ;

G is a C a (OR32) x H 2a+1-x group which has one or more CH 2 groups that may be replaced by O or NR33, a C b (OR32) y H 2b−1-y group which has one or more CH 2 groups that may be replaced by O or NR33, a C c H 2c+1 group which has two or more CH 2 groups that are replaced by O or NR33, a —(CH 2 ) z —COOR34 group, a —(CH 2 ) z —SO 3 R34 group, a —(CH 2 ) z —N + R35R36R37 group which has 1 or 2 hydrogen atoms of the —(CH 2 ) z units that may be replaced by OR32 groups, a —CR38R39-COOR40 group, or a —CR38R39NR41R42 group; where

a is 2, 3, 4, 5, 6, 7 or 8;

x is 2, 3, 4, 5, 6, 7 or 8;

R32 is H, CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 , COCH 3 , COCH 2 CH 3 , COCF 3 or COCH 2 CF 3 ;

R33 is H, CH 3 , CH 2 CH 3 , CF 3 or CH 2 CF 3 ;

b is 3, 4, 5, 6 or 7;

y is 2, 3, 4, 5, 6 or 7;

c is 3, 4, 5, 6, 7 or 8;

z is 1 or 2;

R34, R35, R36 and R37 are each independently H, CH 3 , CH 2 CH 3 , CF 3 or CH 2 CF 3;

R38 is —(CH 2 ) n —Y; where

n is 0, 1, 2, 3 or 4;

Y is H, or alkyl which has 1, 2, 3 or 4 carbon atoms with none, some or all of which being fluorinated and further has one or more CH 2 groups that may be replaced by O, S or NR43, or Y is COOR44, CONR45R46, NHC(NH)NH 2 , phenyl or heteroaryl, where said phenyl or heteroaryl may be substituted by up to 3 substituents independently selected from the group consisting of CH 3 , CF 3 , OH, OCH 3 and NH 2 ; where

R43, R44, R45 and R46 are each independently H, CH 3 , CH 2 CH 3 , CF 3 or CH 2 CF 3 ;

R39 is H, CH 3 , CH 2 CH 3 , CF 3 or CH 2 CF 3 ;

R40 is H, CH 3 , CH 2 CH 3 , CF 3 or CH 2 CF 3 ;

R41 and R42 are each independently H, CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 , COCH 3 , COCH 2 CH 3 , COCF 3 or COCH 2 CF 3 ;

provided that at least one of the R7, R8 or R9 radicals is a -L-G group.

4. A compound of claim 3 , wherein

R1, R2, R3 and R4, are each independently H, F, Cl, Br, CN, NO 2 , OH, —CH 3 , —CH 2 CH 3 , —CF 3 , CH 2 CF 3 , OCH 3 , OCH 2 CH 3 , OCF 3 , OCH 2 CF 3 , SO 2 R10, NR14R15, CONR16R17, COOR18 or OCOR18; where

R10 is CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 , OH or NR11R12; where

R11 and R12 are each independently H, CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 , COCH 3 , COCH 2 CH 3 , COCF 3 or COCH 2 CF 3 ;

R14 and R15 are each independently H, CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 , COCH 3 , COCH 2 CH 3 , COCF 3 or COCH 2 CF 3 ;

R16 and R17 are each independently H, CH 3 , CH 2 CH 3 , CF 3 or CH 2 CF 3 ;

R18 is H, CH 3 , CH 2 CH 3 , CF 3 or CH 2 CF 3 ;

R5 is CH 3 ;

R6 is H;

R7, R8 and R9 are each independently H, F, Cl, Br, I, OH, CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 , OCH 3 , OCH 2 CH 3 , OCF 3 , OCH 2 CF 3 , SO 2 R47, SO 3 R60, COR47, COOR60, NR51R52 or a -L-G group; where

R47 is H, CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 or NR48R49; where

R48 and R49 are each independently H, CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 , COCH 3 , COCH 2 CH 3 , COCF 3 or COCH 2 CF 3 ,

or R48 and R49 are, together with the nitrogen atom which bonds them, part of a 5- or 6-membered ring which is of a type selected from the group consisting of 1-pyrrolyl, 1-piperidinyl, 1-piperazinyl, 1-N-methylpiperazinyl and 4-morpholinyl;

R60 is H, CH 3 , CH 2 CH 3 , CF 3 , or CH 2 CF 3 ;

R51 and R52 are each independently H, CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 , COCH 3 , COCH 2 CH 3 , COCF 3 or COCH 2 CF 3

or R51 and R52 are, together with the nitrogen atom which bonds them, part of a 5- or 6-membered ring which is of a type selected from the group consisting of 1-pyrrolyl, 1-piperidinyl, 1-piperazinyl, 1-N-methylpiperazinyl and 4-morpholinyl;

L is —NR30CO—, —CONR30-, —NR30CONR31-, OR—NR30COO—, and where

R30 and R31 are each independently H, —CH 3 , —CH 2 CH 3 , —CF 3 or —CH 2 CF 3 ;

G is a C a (OR32) x H 2a+1-x group which has one or more CH 2 groups that may be replaced by O or NR33, a C b (OR32) y H 2b−1-y group which has one or more CH 2 groups that may be replaced by O or NR33, a C c H 2c+1 group which has two or more CH 2 groups that are replaced by O or NR33, a —(CH 2 ) z —COOR34 group, a —(CH 2 ) z —SO 3 R34 group, a —(CH 2 ) z —N 30 R35R36R37 group which has 1 or 2 hydrogen atoms of the —(CH 2 ) z units that may be replaced by OR32 groups, a —CR38R39—COOR40 group or a —CR38R39NR41R42 group; where

a is 2, 3, 4, 5, 6, 7 or 8;

x is 2, 3, 4, 5, 6, 7 or 8;

R32 is H, CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 , COCH 3 , COCH 2 CH 3 , COCF 3 or COCH 2 CF 3 ;

R33 is H, CH 3, CH 2 CH 3 , CF 3 or CH 2 CF 3 ;

b is 3, 4, 5, 6 or 7;

y is 2, 3, 4, 5, 6 or 7;

c is 3, 4, 5, 6, 7 or 8;

z is 1 or 2;

R34, R35, R36 and R37 are each independently H, CH 3 , CH 2 CH 3 , CF 3 or CH 2 CF 3 ;

R38 is —(CH 2 ) n —Y; where

n 0, 1, 2, 3 or 4;

Y is H, or alkyl which has 1, 2, 3 or 4 carbon atoms with none, some or all of the carbon atoms being fluorinated and further has one or more CH 2 groups that may be replaced by O, S or NR43, or Y is COOR44, CONR45R46, NHC(NH)N 2 , phenyl or heteroaryl, where said phenyl or heteroaryl may be substituted by up to 3 substituents selected from the group consisting of CH 3 , CF 3 , OH, OCH 3 and NH 2 ; where

R43, R44, R45 and R46 are each independently H, CH 3 , CH 2 CH 3 , CF 3 or CH 2 CF 3 ,

R39 is H;

R40 is H, CH 3 , CH 2 CH 3 , CF 3 or CH 2 CF 3 ;

R41 and R42 are each independently H, CH 3 , CH 2 CH 3 , CF 3 , CH 2 CF 3 , COCH 3 , COCH 2 CH 3 , COCF 3 or COCH 2 CF 3 ;

provided that at least one of the R7, R8 or R9 radicals is a -L-G group.

5. A compound of claim 1 selected from the group consisting of

N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2,3,4,5,6-pentahydroxyhexanamide,

N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2,3,4,5,6-pentahydroxyhexanamide,

N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2,3,4,5,6-pentahydroxyhexanamide,

N-[3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2,3,4,5,6-pentahydroxyhexanamide,

N-[3-((R)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2,3,4,5,6-pentahydroxyhexanamide,

1-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-(2-hydroxy-1-hydroxymethylethyl)urea,

1-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-(2-hydroxy-1,1-bishydroxymethylethyl)urea,

1-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-(2,3,4,5,6-pentahydroxyhexyl)urea,

1-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-(2,4,5-trihydroxy-6-hydroxymethyhetrahydropyran-3-yl)urea,

{N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-N′-(1-sulfo-2-ethyl)}urea,

{N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-N′-(ethyl-2-trimethylammonium)}urea chloride,

{N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-N′(1-carboxy-3-hydroxy-2-propyl)}urea,

{N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-N′-(1-carboxy-4-aminocarboxy-2-butyl)}urea,

3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-(2,3,4,5,6-pentahydroxyhexyl)benzamide,

3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-(2-hydroxy-1-hydroxymethylethyl)benzamide,

2-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)benzoylamino]-3-hydroxypropionic acid,

2-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)benzoylamino]succinic acid,

2-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)benzoylamino]-4-succinamic acid,

N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-N′-[1-carboxy-5-guanidino-2-pentyl]urea,

{N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-N′-(1-carboxy-4-aminocarboxy-2-butyl)}urea,

{N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-N′-(1-carboxy-3-hydroxy-2-propyl)}urea,

1-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-(2-hydroxy -1,1-bishydroxymethylethyl)urea,

1-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-(2,3,4,5,6-pentahydroxyhexyl)urea,

5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N,N′-bis(2-hydroxy-1-hydroxymethylethyl)isophthalamide,

5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N,N′-bis(2-hydroxy-1,1-bishydroxymethylethyl)isophthalamide,

5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-bis(2-hydroxy-1,1-bishydroxymethylethyl)isophthalamide,

5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N,N′-bis(2,3,4,5,6-pentahydroxyhexyl)isophthalamide,

5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-(2,3,4,5,6-pentahydroxyhexyl)isophthalamide,

2-[3-(1-carboxy-2-hydroxyethylcarbamoyl)-5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)benzoylamino]-3-hydroxypropionic acid,

N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2-amino-5-guanidinopentanamide,

N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2-amino-5-guanidinopentanamide,

2-amino-N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-(1H-imidazol-4-yl)propionamide,

2-amino-N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-(1H-imidazol-4-yl)propionamide,

ethyl{3-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]ureido}-acetate,

ethyl{3-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]ureido}-acetate,

ethyl{3-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]ureido}-acetate,

{3-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]ureido}acetic acid,

{3-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]ureido}acetic acid,

{3-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]ureido}acetic acid,

ethyl{3-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(R)-yl)phenyl]ureido}-acetate,

ethyl{3-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(S)-yl)phenyl]ureido}-acetate,

ethyl{3-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(R)-yl)phenyl]ureido}-acetate,

ethyl{3-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(S)-yl)phenyl]ureido}-acetate,

ethyl{3-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(R)-yl)phenyl]ureido}-acetate,

ethyl{3-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(S)-yl)phenyl]ureido}-acetate,

{3-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(R)-yl)phenyl]ureido}acetic acid,

{3-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(S)-yl)phenyl]ureido}acetic acid,

{3-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(R)-yl)phenyl]ureido}acetic acid,

{3-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(S)-yl)phenyl]ureido}acetic acid,

{3-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(R)-yl)phenyl]ureido}acetic acid,

{3-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(S)-yl)phenyl]ureido}acetic acid,

2-methoxyethyl[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(R)-yl)phenyl]-carbamate,

2-methoxyethyl[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(S)-yl)phenyl]-carbamate,

2-methoxyethyl[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(R)-yl)phenyl]-carbamate, and

2-methoxyethyl[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(S)-yl)phenyl]-carbamate.

6. A compound of claim 5 which is selected from the group consisting of

N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanamide,

N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanamide,

N-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-(2R,3S,4R, 5R)-2,3,4,5,6-pentahydroxyhexanamide,

N-[3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanamide,

N-[3-((R)-6,3-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-(2R,3S,4R,5R)-2,3,4,5,6-pentahydroxyhexanamide,

1-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-(2-hydroxy-1-hydroxymethylethyl)urea,

1-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-(2-hydroxy-1,1-bishydroxymethylethyl)urea,

1-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)urea,

1-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-((4R,5S,6R)-2,4,5-trihydroxy-6-hydroxymethyltetrahydropyran-3-yl)urea,

{N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-N′-(1-sulfo-2-ethyl)}urea,

{N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-N′-(ethyl-2-trimethylammonium)}urea chloride,

{N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-N′-(1-carboxy -3-hydroxy-2S-propyl)}urea,

{N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-N′-(1-carboxy -4-aminocarboxy-2S-butyl)}urea,

3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-((2S,3R,4R,5R) -2,3,4,5,6-pentahydroxyhexyl)benzamide,

3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-(2-hydroxy-1-hydroxymethylethyl)benzamide,

2-(S)-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)benzoylamino]-3-hydroxypropionic acid,

2-(S)-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)benzoylamino]succinic acid,

2-(S)-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)benzoylamino]-4-succinamic acid,

N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-N′-[1-carboxy -5-guanidino-2S-pentyl]urea,

{N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-(R)-yl)phenyl]-N′-(1-carboxy-4-aminocarboxy-2S-butyl)}urea,

{N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-(S)-yl)phenyl]-N′-(1-carboxy-4-aminocarboxy-2S-butyl)}urea,

{N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-(R)-yl)phenyl]-N′-(1-carboxy-3-hydroxy-2S-propyl)}urea,

{N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-(S)-yl)phenyl]-N′-(1-carboxy-3-hydroxy-2S-propyl)}urea,

1-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-(R)-yl)phenyl]-3-(2-hydroxy-1,1-bishydroxymethylethyl)urea,

1-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-(S)-yl)phenyl]-3-(2-hydroxy-1,1-bishydroxymethylethyl)urea,

1-[3-((R)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-((2S,3R, 4R,5R)-2,3,4,5,6-pentahydroxyhexyl)urea,

1-[3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-((2S,3R, 4R,5R)-2,3,4,5,6-pentahydroxyhexyl)urea,

5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N,N′-bis(2-hydroxy-1-hydroxymethylethyl)isophthalamide,

5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N,N′-bis(2-hydroxy-1,1-bishydroxymethylethyl)isophthalamide,

5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-(2-hydroxy-1,1-bishydroxymethylethyl)isophthalamide,

5(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N,N′-bis((2S,3R,4R, 5R)-2,3,4,5,6-pentahydroxyhexyl)isophthal amide,

5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-((2S,3R,4R,5R) -2,3,4,5,6-pentahydroxyhexyl)isophthalamide,

(S)-2-[3-((S)-1-carboxy-2-hydroxyethylcarbamoyl)-5-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)benzoylamino]-3-hydroxypropionic acid,

(S)-N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2-amino-5-guanidinopentanamide,

(S)-N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-2-amino-5-guanidinopentanamide,

(S)-2-amino-N-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-(1H-imidazol-4-yl)propionamide,

(S)-2-amino-N-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]-3-(1H-imidazol-4-yl)propionamide,

ethyl{3-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]ureido}-acetate,

ethyl{3-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]ureido}-acetate,

ethyl{3-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]ureido}-acetate,

{3-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]ureido}acetic acid,

{3-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]ureido}acetic acid,

{3-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl]ureido}acetic acid,

ethyl{3-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(R)-yl)phenyl]ureido}-acetate,

ethyl{3-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(S)-yl)phenyl]ureido}-acetate,

ethyl{3-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(R)-yl)phenyl]ureido}-acetate,

ethyl{3-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(S)-yl)phenyl]ureido}-acetate,

ethyl{3-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(R)-yl)phenyl]ureido}-acetate,

ethyl{3-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(S)-yl)phenyl]ureido}-acetate,

{3-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(R)-yl)phenyl]ureido}acetic acid,

{3-[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(S)-yl)phenyl]ureido}acetic acid,

{3-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(R)-yl)phenyl]ureido}acetic acid,

{3-[2-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(S)-yl)phenyl]ureido}acetic acid,

{3-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(R)-yl)phenyl]ureido}acetic acid,

{3-[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(S)-yl)phenyl]ureido}acetic acid,

2-methoxyethyl[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(R)-yl)phenyl]-carbamate,

2-methoxyethyl[4-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(S)-yl)phenyl]-carbamate,

2-methoxyethyl[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(R)-yl)phenyl]-carbamate, and

2-methoxyethyl[3-(6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4(S)-yl)phenyl]-carbamate.

7. A medicament comprising a compound as recited in claim 1 for human, veterinary or phytoprotective use further comprising other pharmacological active ingredients in admixture with one or more pharmaceutically acceptable inactive excipients.

8. A method of treatment or prophylaxis, by administering to a mammal a medicament comprising a compound of claim 1 in a pharmaceutically acceptable formulation, for disorders of respiratory drive, respiratory disorders, sleep-related respiratory disorders, sleep apneas, snoring, of acute and chronic renal disorders, acute renal failure and of chronic renal failure, disorders of intestinal function, high blood pressure, essential hypertension, disorders of the central nervous system, disorders resulting from CNS over-excitability, epilepsy and centrally induced convulsions or of anxiety states, depressions and psychoses, ischemic states of the peripheral or central nervous system and of stroke, acute and chronic damage to and disorders of peripheral organs or limbs caused by ischemic or by reperfusion events, atherosclerosis, disorders of lipid metabolism, thromboses, disorders of biliary function, infestation by ectoparasites, disorders resulting from endothelial dysfunction, protozoal disorders, malaria, for the preservation and storage of transplants for surgical procedures, for use in surgical operations and organ transplantations or for the treatment of states of shock or of diabetes and late damage from diabetes or of diseases in which cellular proliferation represents a primary or secondary cause.

9. The method of claim 8 , wherein said medicament further comprises another medicament or active ingredient.

10. A method of claim 8 , wherein said method is for the treatment or prophylaxis of disorders of respiratory drive andlor of sleep-related respiratory disorders comprising sleep apneas.

11. A method of claim 8 , wherein said method is for the treatment or prophylaxis of snoring.

12. A method of claim 8 , wherein said method is for the treatment or prophylaxis of acute or chronic renal disorders, of acute renal failure and of chronic renal failure.

13. A method of claim 8 , wherein said method is for the treatment or prophylaxis of disorders of intestinal function.

Assignments (4)
SECURITY INTEREST Recorded Dec 7, 2022
From: SIO2 MEDICAL PRODUCTS, INC.
To: SALZUFER HOLDING INC., AS ADMINISTRATIVE AGENT
Reel/Frame 062094/0121 →
SECURITY AGREEMENT AMENDMENT Recorded Apr 7, 2021
From: SIO2 MEDICAL PRODUCTS, INC.
To: THE TEACHERS' RETIREMENT SYSTEM OF ALABAMA
Reel/Frame 055852/0007 →
CHANGE OF NAME Recorded Nov 18, 2005
From: AVENTIS PHARMA DEUTSCHLAND GMBH
To: SANOFI-AVENTIS DEUTSCHLAND GMBH
Reel/Frame 016793/0789 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 21, 2004
From: HOFMEISTER, DR. ARMIN; HEINELT, DR, UWE; LANG, DR. HANS-JOCHEN; FRICK, DR. WENDELIN; BLEICH, DR. MARKUS; WIRTH, DR. KLAUS
To: AVENTIS PHARMA DEUTSCHLAND GMBH
Reel/Frame 015153/0532 →
Priority Claims (1)
DE 103 12 963 · Mar 24, 2003 · national
Continuity (2)
Provisional Application 6049385900 · Aug 8, 2003
Related Publication 20050009863A1 · Jan 13, 2005